Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,676.78
+13.740.83%
Number of Gainers:15
Number of Losers:4
Number of Flat:- -
PE:- -
High:1,681.81
Open:1,663.44
Low:1,657.00
Close:1,663.06
Volume:72.11M
Turnover:1.35B
Market Cap:1.37T
Float Cap:1.35T

Loading ...

Pfizer CEO Bourla speaks at Jefferies Global Healthcare Conference webcast

Reuters
·
1 hour ago

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:59 AM

Reuters
·
1 hour ago

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR)

TIPRANKS
·
1 hour ago

Abbott wins CE Mark for Libre Duo dual glucose-ketone sensor in Europe

Reuters
·
1 hour ago

Abbott Secures Ce Mark for World's First Dual Glucose-Ketone Sensing Technology for People With Diabetes

THOMSON REUTERS
·
1 hour ago

Lakeland Industries schedules conference call on fiscal Q1 2027 results

Reuters
·
2 hours ago

Lakeland Fire + Safety to Host Fiscal First Quarter 2027 Financial Results Conference Call on Tuesday, June 9, 2026 at 4:30 p.m. Eastern Time

GlobeNewswire
·
2 hours ago

UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117

MT Newswires Live
·
3 hours ago

AstraZeneca says FDA extends PDUFA date to review camizestrant data for NDA

TIPRANKS
·
3 hours ago

Abbott: ACS releases updated CRC guidelines reaffirm Cologuard, Cologuard Plus

TIPRANKS
·
3 hours ago

Top Premarket Gainers

MT Newswires Live
·
3 hours ago

APT Satellite Mourns Veteran Non-Executive Director as Board Line-Up Shifts

TIPRANKS
·
4 hours ago

APT Satellite Reshapes Board Committees to Strengthen Governance Oversight

TIPRANKS
·
4 hours ago

BioNTech upgraded to Buy from Neutral at UBS

TIPRANKS
·
6 hours ago

Gilead Sciences Says Liver Drug Phase 3 Trial Shows Sustained Normalization of Key Disease Marker

MT Newswires Live
·
6 hours ago

Pfizer's Key Anti-Infective Drug Gains New Pediatric Formulation Approval in China, Enhancing Invasive Fungal Disease Treatment for Children

Stock News
·
7 hours ago

AstraZeneca Says FDA Extends Regulatory Review of New Drug Application of its Combination Breast Cancer Treatment

MT Newswires Live
·
7 hours ago

Gilead: Further Analyses of Phase 3 Assure Study Demonstrate Sustained Alp Normalization

THOMSON REUTERS
·
8 hours ago

Gilead - Livdelzi Generally Well Tolerated With No New Safety Signals Over Two Years

THOMSON REUTERS
·
8 hours ago

Assembly Bio publishes corporate presentation on clinical-stage antiviral and liver disease pipeline, Gilead partnership

Reuters
·
8 hours ago